Tempus AI Q3 2026 earnings

TEM · 2026-11-02 07:00 BMO ET · 8-K on SEC · 10-Q on SEC

Revenue accelerated to 23% YoY, gross profit grew 27%, and Adjusted EBITDA swung to a positive $25.6 million from $1.5 million a year ago.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$411.5 million+23.0%+7.6%Ex. 99.1, income statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
Diagnostics$303.5 million+20.0%73.7%Oncology volume growth 32%, offset by Hereditary growth of 3%
Data and applications$108.1 million+33.0%26.3%Insights growing 29%

Margins and costs

  • Gross margin 64.8% (prior 62.8%, change +2.0 pp)
  • Operating expenses $323.6 million (+20.0% YoY)
  • One-offs in the quarter Stock-based compensation expense $50.8 million; Unrealized gains on marketable securities $42.8 million; Acquisition related expenses $3.7 million; Losses from equity method investments $2.4 million
  • Effective tax rate -0.01% (prior-year -0.1%, year-to-date -0.2%)
  • Non-GAAP bridge Adds back stock-based compensation, acquisition-related expenses, amortization of intangibles, franchise taxes, losses/gains on equity investments, fair value changes, interest, and loss on debt extinguishment.

KPIs

MetricActualPrior quarterPrior yearChange
Oncology volume growth32%31%28%+4 pp
MRD volume~12,000 tests~9,000 testsN/A+300%
Insights revenue growth29%36%N/A-7 pp

Guidance

MetricGuidePrior guideChange
Full year 2026 revenue$1.60 to $1.605 billion$1.595 to $1.605 billion+$5 million midpoint
Full year 2026 Adjusted EBITDA~$65 million~$65 millionNo change

What drove it

  • Revenue story Total revenue grew 23% YoY to $411.5 million, driven by 32% oncology volume growth in Diagnostics and 33% growth in Data and Applications.
  • EPS story Net loss improved to $(14.9) million from $(80.0) million YoY, driven by higher revenue, improved gross margins, and a large swing in unrealized gains on marketable securities.
  • One-off check Unrealized gains on marketable securities of $42.8 million and stock-based compensation expense of $50.8 million are the primary non-recurring items in the quarter.

The good

  • Adjusted EBITDA turned positive to $25.6 million from $1.5 million a year ago
  • Oncology volume growth accelerated to 32%
  • Data and Applications revenue grew 33%

The bad

  • Net loss remains at $(14.9) million
  • Operating loss widened to $(56.9) million from $(61.0) million YoY

The ugly

  • none

Open questions

  • How will the Personalis acquisition impact revenue and Adjusted EBITDA guidance?
  • What is the expected timing for the Personalis shareholder meeting and closing?
Full release

Tempus AI (TEM) earnings release, November 2, 2026

Tempus AI, Inc. (TEM) · Form 8-K, Item 2.02 · Filed · SEC filing

Tempus Reports Third Quarter 2026 Results

CHICAGO, November 2, 2026 — Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today reported financial results for the quarter ended September 30, 2026.

“Q3 was another record quarter, as we delivered $411.5 million of revenue, led by accelerating unit growth of 32% in our oncology business and increasing momentum of 33% revenue growth in Data & Applications,” said Eric Lefkofsky, founder and CEO of Tempus. “These results reinforce the durability of our model as our best-in-class diagnostic platform enhances our data and AI offerings, distinguishes our business from our many competitors, and helps drive our performance quarter after quarter.”

Third Quarter 2026 Highlights

For the three-month period ended September 30, 2026, as compared to the same period in 2025:

• Total revenue of $411.5 million, an increase of 23%

• Oncology volume growth accelerated to 32%

• Minimal Residual Disease (MRD) volume of ~12,000 tests, up 300%

• Data & Apps revenue increased 33%, with Insights increasing 29%

• Increasing full year 2026 revenue guidance to $1.60 to $1.605 billion and expect full year Adjusted EBITDA of ~$65 million

• Announced multi-year strategic collaboration with Merck and Moderna to support commercialization of their individualized neoantigen therapy (INT) class of drugs

• In October, announced a strategic collaboration with BMS bringing Tempus’ total data licensing bookings to >$550 million year to date

Third Quarter 2026 Summary Results

For the three-month period ended September 30, 2026, as compared to the same period in 2025:

• Total revenue increased 23% to $411.5 million.

• Diagnostics generated $303.5 million of revenue, representing 20% growth, driven by Oncology volume growth of 32%, offset by Hereditary revenue growth of 3%.

• Data and Applications generated $108.1 million of revenue, representing 33% growth, with Insights growing 29%.

• Gross profit increased 27% to $266.7 million, led by growth in Data and Applications.

• Net loss was $(14.9) million, which included $50.8 million of stock-based compensation expense and related employer payroll taxes and $42.8 million in unrealized gains on marketable securities, compared to a net loss of $(80.0) million in Q3 of 2025.

• Adjusted EBITDA was $25.6 million, compared to $1.5 million in Q3 of 2025.

• Ended the quarter with cash and marketable securities of $854.4 million.

Detailed Operational Highlights

• Announced a strategic collaboration with BMS in October through which Tempus is directly licensing to BMS oncology data and models for up to $137.5 million over a five-year term. In addition, BMS and Pathos are licensing data for patients with Alzheimer's or dementia for $55 million over a five-year term, extending Tempus’ data and modeling platform beyond oncology.

• Announced a multi-year strategic collaboration with Merck and Moderna to support the potential commercialization of intismeran autogene, a novel, potential first-in-class individualized neoantigen therapy (INT) being evaluated in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with completed resected stage IIB-IV melanoma and other cancer types.

• Cleared regulatory review of pending acquisition of Personalis (Nasdaq: PSNL). Personalis' shareholder meeting to approve the acquisition is planned for November 30, 2026.

• Received two 510(k) clearances from the U.S. Food and Drug Administration (FDA) for Tempus ECG-PH and ECG-MR, expanding our non-invasive AI cardiology footprint.

• Announced an initiative to build a research platform containing 100,000 whole genomes linked to longitudinal clinical information over the next several years.

Third Quarter Financial Results

Financial Outlook and Guidance

Tempus is increasing its full year 2026 revenue guidance to $1.60 to $1.605 billion, which represents ~25% annual growth. We continue to expect 2026 Adjusted EBITDA to be ~$65 million.

For additional information on the quarter, including a letter from our CEO and CFO, please visit our investor relations site at investors.tempus.com.

Webcast and Conference Call Information

A conference call and webcast will begin today, November 2, 2026 at 8:45 a.m. Eastern Time. Interested parties may access details at:

Conference ID: 579 261 752

United States (Toll-Free): (833) 461-5787

International (Toll): +1 (585) 542-9983

Live webcast can be accessed here

The webcast may be accessed on the company’s investor relations website at investors.tempus.com. For those unable to listen to the live webcast, a recording will be made available on the company’s website after the event and will be accessible for one year. Visit the investor relations website to find the company’s latest deck, and commentary on the quarter by Eric Lefkofsky, Founder and CEO, and Jim Rogers, CFO, which will be discussed on the conference call and webcast.

About Tempus

Tempus is a technology company making precision medicine a reality through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of de-identified multimodal data and an intelligent operating system that makes that data accessible and actionable, Tempus connects AI, diagnostics and clinical workflows to deliver more personalized patient care and accelerate the discovery, development and delivery of better medicines. By continuously transforming data into insights, Tempus is building a learning healthcare ecosystem in which every patient can benefit from the treatment and experiences of those who came before.

For more information, visit tempus.com and follow Tempus on

LinkedIn,

Instagram, and

X.

Non-GAAP Financial Measures... (truncated)merica (GAAP), Tempus also presents adjusted non-GAAP financial measures.

Non-GAAP gross profit is defined as GAAP gross profit, excluding stock-based compensation expense and employer payroll tax related to stock-based compensation (collectively, the “stock-based compensation adjustments”).

Non-GAAP gross margin is defined as gross profit, excluding the stock-based compensation adjustments, as a percentage of revenue.

Non-GAAP operating expenses are calculated as the sum of technology research and development expense, research and development expense, and selling, general and administrative expense, excluding the stock-based compensation adjustments, acquisition-related expenses, amortization of intangibles due to acquisition, and franchise taxes related to IPO.

Non-GAAP income (loss) from operations is defined as loss from operations, adjusted to exclude (i) the stock-based compensation adjustments, (ii) acquisition-related expenses, (iii) franchise taxes related to IPO, and (iv) amortization of intangibles due to acquisition.

Non-GAAP net income (loss) is defined as net loss, adjusted to exclude (i) changes in fair value of our marketable equity securities and indemnity-related holdback liabilities, (ii) the stock-based compensation adjustments, (iii) acquisition-related expenses, (iv) amortization of intangibles due to acquisition, (v) losses (gains) from equity method investments, (vi) provision for (benefit from) income taxes, (vii) franchise taxes related to IPO, (viii) amortization of deferred other income from our IP License Agreement with SB Tempus, and (ix) loss on debt extinguishment.

Non-GAAP net income (loss) per share is defined as non-GAAP net income (loss) divided by weighted average common shares outstanding, basic and diluted.

Adjusted EBITDA is defined as net loss, adjusted to exclude (i) interest income, (ii) interest expense, (iii) depreciation and amortization, (iv) provision for (benefit from) income taxes, (v) losses (gains) from equity method investments, (vi) changes in fair value of our marketable equity securities and indemnity-related holdback liabilities, (vii) the stock-based compensation adjustments, (viii) acquisition-related expenses, (ix) amortization of deferred other income from our IP License Agreement with SB Tempus, (x) franchise taxes related to our IPO, and (xi) loss on debt extinguishment.

Tempus believes these non-GAAP financial measures are useful to investors and others because they allow for additional information with respect to financial measures used by management in its financial and operational decision-making and they may be used by institutional investors and the analyst community to help them analyze the health of Tempus’ business. In particular, Adjusted EBITDA is a key measurement used by Tempus management to make operating decisions, including those related to analyzing operating expenses, evaluating performance, and performing strategic planning and annual budgeting. However, there are a number of limitations related to the use of non-GAAP financial measures, and these non-GAAP measures should be considered in addition to, not as a substitute for or in isolation from, our financial results prepared in accordance with GAAP. Other companies, including companies in our industry, may calculate these non-GAAP financial measures differently or not at all, which reduces their usefulness as comparative measures.

Tempus does not provide guidance for net loss, the most directly comparable GAAP measure to Adjusted EBITDA, and similarly cannot provide a reconciliation between Tempus’ forecasted Adjusted EBITDA and net loss without unreasonable effort due to the unavailability of reliable estimates for certain components of net loss and the respective reconciliations. These forecasted items are not within Tempus’ control, may vary greatly between periods, and could significantly impact future financial results.

Forward Looking Statements

Financial statements

Income Statement

Three Months Ended September 30, — Third Quarter Financial Results (in thousands, except percentages and per share amounts)

Three Months Ended September 30, – 2026 – (unaudited)Three Months Ended September 30, – 2025 – (unaudited)Change
Revenue411,537334,20623.0%
Gross profit266,701209,94227.0%
Loss from operations-56,864-60,9967.0%
Non-GAAP income (loss) from operations14,422-8,662267.0%
Net loss-14,851-79,98281.0%
Non-GAAP net income (loss)13,359-19,590168.0%
Adjusted EBITDA25,5721,4761633.0%
Net loss per share, basic and diluted-0.08-0.4683.0%
Non-GAAP net income (loss) per share, basic and diluted0.07-0.11164.0%

Income Statement

Three Months Ended September 30, — (in thousands, except per share amounts)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Net revenue
Diagnostics(1)303,470252,878853,901688,525
Data and applications(2)108,06781,328288,238216,053
Total net revenue411,537334,2061,142,139904,578
Cost and operating expenses
Cost of revenues, diagnostics114,04298,643323,235283,182
Cost of revenues, data and applications30,79425,62183,66461,212
Technology research and development45,70838,087135,558105,960
Research and development46,00044,960146,874122,453
Selling, general and administrative231,857187,891670,296523,230
Total cost and operating expenses468,401395,2021,359,6271,096,037
Loss from operations-56,864-60,996-217,488-191,459
Interest income3,9854,60011,7487,506
Interest expense-6,701-15,399-31,325-54,981
Loss on debt extinguishment-12,034-11,643-12,034
Other income, net(3)47,1322,605122,18016,879
Loss before (provision for) benefit from income taxes-12,448-81,224-126,528-234,089
(Provision for) benefit from income taxes-35-276-28245,692
(Losses) gains from equity method investments-2,3681,518-8,318-2,465
Net loss-14,851-79,982-135,128-190,862
Net loss per share, basic and diluted-0.08-0.46-0.75-1.1
Weighted-average shares outstanding used to compute net loss per share, basic and diluted181,311174,945180,049172,969
Comprehensive loss, net of tax
Net loss-14,851-79,982-135,128-190,862
Foreign currency translation adjustment2,107-2,915-7365,439
Comprehensive loss-12,744-82,897-135,864-185,423

Income Statement

Three Months Ended September 30, — Diagnostics Gross Profit & Gross Margin (in thousands)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Diagnostics revenue303,470252,878853,901688,525
Cost of revenues, diagnostics114,04298,643323,235283,182
Gross profit, diagnostics189,428154,235530,666405,343
Stock-based compensation expense3,0371,6318,7954,086
Employer payroll tax related to stock-based compensation15036608338
Non-GAAP gross profit, diagnostics192,615155,902540,069409,767
Diagnostics gross margin62.4%6162.1%58.9
Stock-based compensation expense1.0%0.61.0%0.6
Employer payroll tax related to stock-based compensation0.0%00.1%0
Non-GAAP gross margin, diagnostics63.5%61.763.2%59.5

Income Statement

Three Months Ended September 30, — Data and applications Gross Profit & Gross Margin

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Data and applications revenue108,06781,328288,238216,053
Cost of revenues, data and applications30,79425,62183,66461,212
Gross profit, data and applications77,27355,707204,574154,841
Stock-based compensation expense1,2148943,7352,198
Employer payroll tax related to stock-based compensation9462331220
Non-GAAP gross profit, data and applications78,58156,663208,640157,259
Gross margin, data and applications71.5%68.571.0%71.7
Stock-based compensation expense1.1%1.11.3%1
Employer payroll tax related to stock-based compensation0.1%0.10.1%0.1
Non-GAAP gross margin, data and applications72.7%69.772.4%72.8

Income Statement

Three Months Ended September 30, — Total Gross Profit & Gross Margin

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Net revenue411,537334,2061,142,139904,578
Cost of revenues144,836124,264406,899344,394
Gross profit266,701209,942735,240560,184
Stock-based compensation expense4,2512,52512,5306,284
Employer payroll tax related to stock-based compensation24598940558
Non-GAAP gross profit271,197212,565748,710567,026
Gross margin64.8%62.864.4%61.9
Stock-based compensation expense1.0%0.81.1%0.7

Income Statement

Three Months Ended September 30, — Operating Expenses

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Technology research and development45,70838,087135,558105,960
Stock-based compensation expense7,9545,46326,10112,067
Employer payroll tax related to stock-based compensation6152781,7851,034
Non-GAAP technology research and development37,13932,346107,67292,859
Research and development46,00044,960146,874122,453
Stock-based compensation expense5,4323,30115,2847,618
Employer payroll tax related to stock-based compensation2741221,005533
Non-GAAP research and development40,29441,537130,585114,302
Selling, general and administrative231,857187,891670,296523,230
Stock-based compensation expense30,43722,690100,98653,439
Employer payroll tax related to stock-based compensation1,6155414,0716,040
Acquisition related expenses(1)3,7285524,7146,073
Amortization of intangibles due to acquisition16,73516,76450,20744,691
Franchise taxes related to IPO1,647
Non-GAAP selling, general and administrative179,342147,344510,318411,340
Operating expenses323,565270,938952,728751,643
Stock-based compensation expense43,82331,454142,37173,124
Employer payroll tax related to stock-based compensation2,5039416,8607,607
Acquisition related expenses(1)3,7285524,7146,073
Amortization of intangibles due to acquisition16,73516,76450,20744,691
Franchise taxes related to IPO1,647
Non-GAAP operating expenses256,776221,227748,576618,501

Balance Sheet

September 30, 2026 — (in thousands, except share and per share amounts)

September 30, 2026December 31, 2025
Current Assets
Cash and cash equivalents590,479604,787
Accounts receivable(1), net of allowances of $4,378 and $2,755 at September 30, 2026 and December 31, 2025, respectively380,744311,170
Inventory53,77351,724
Related party asset17,5008,785
Prepaid expenses and other current assets47,50740,498
Marketable equity securities46,874150,211
Total current assets1,136,8771,167,175
Property and equipment, net95,18689,156
Goodwill488,142470,211
Intangible assets, net293,815349,202
Capitalized software, net40,5616,051
Marketable equity securities, less current portion212,276
Investments and other assets16,24121,111
Investment in joint venture77,63586,557
Investment in related party17,500
Related party asset, less current portion10,20816,215
Operating lease right-of-use assets58,40264,496
Restricted cash4,7554,664
Total Assets2,451,5982,274,838
Current Liabilities
Accounts payable70,50681,994
Related party payable10,000
Accrued expenses232,976155,370
Deferred revenue(2)85,93192,673
Deferred other income(3)11,96615,955
Other current liabilities12,1468,680
Operating lease liabilities11,58413,355
Accrued data licensing fees1,2964,361
Total current liabilities436,405372,388

Balance Sheet

September 30, 2026 — (in thousands, except share and per share amounts)

September 30, 2026December 31, 2025
Operating lease liabilities, less current portion69,48374,272
Convertible promissory note175,967208,672
Other long-term liabilities51,44956,600
Revolving credit facility100,000
Interest payable22,50112,393
Long-term debt, net202,753
Convertible senior notes, net1,174,877728,078
Deferred other income, less current portion(3)7,977
Deferred revenue, less current portion20,51420,379
Total Liabilities1,951,1961,783,512
Commitments and contingencies (Note 8)
Convertible redeemable preferred stock, $0.0001 par value, 20,000,000 shares authorized at September 30, 2026 and December 31, 2025, respectively, no shares outstanding at September 30, 2026 and December 31, 2025$—$—
Stockholders' equity
Class A Common Stock, $0.0001 par value, 1,000,000,000 shares authorized at September 30, 2026 and December 31, 2025, respectively; 177,182,062 and 173,235,428 shares outstanding at September 30, 2026 and December 31, 2025, respectively1817
Class B Common Stock, $0.0001 par value, 5,500,000 shares authorized at September 30, 2026 and December 31, 2025, respectively; 5,043,789 outstanding at September 30, 2026 and December 31, 2025, respectively11
Treasury Stock, 203,431 and 183,229 shares at September 30, 2026 and December 31, 2025, respectively, at cost-6,642-6,642
Additional paid-in capital3,037,8492,892,910
Accumulated other comprehensive income166902
Accumulated deficit-2,530,990-2,395,862
Total Stockholders' equity500,402491,326
Total Liabilities, Convertible redeemable preferred stock, and Stockholders' equity2,451,5982,274,838

Cash Flow

Nine Months Ended September 30, — (in thousands)

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Investing activities
Purchases of property and equipment-23,665-16,294
Proceeds from sale of marketable equity securities8,316
Business combinations, net of cash acquired (Note 4)-2,763-375,025
Capitalized software costs-12,252-4,635
Net cash used in investing activities-38,680-387,638
Financing activities
Proceeds from convertible senior notes, net of initial purchasers' discount443,132726,497
Principal payments on long-term debt-207,717-276,892
Principal payments on revolving credit facility-100,000
Prepayment premium on long-term debt-6,433-7,841
Payment of deferred offering costs-264-501
Purchases of capped call-31,234-41,775
Proceeds from revolving credit facility, net of original issue discount98,000
Proceeds from long-term debt, net of original issue discount196,000
Proceeds from issuance of common stock in connection with at-the-market offering, net of commissions195,499
Payment of deferred financing fees-1,349-1,255
Net cash provided by financing activities96,135887,732
Effect of foreign exchange rates on cash-86-78
Net (decrease) increase in Cash, Cash Equivalents and Restricted Cash-14,217318,714
Cash, cash equivalents and restricted cash, beginning of period609,451341,835
Cash, cash equivalents and restricted cash, end of period595,234660,549
Cash, Cash Equivalents and Restricted Cash are Comprised of:
Cash and cash equivalents590,479655,918
Restricted cash and cash equivalents4,7554,631
Total cash, cash equivalents and restricted cash595,234660,549
Supplemental disclosure of cash flow information
Cash paid during the year for interest15,11137,349
Cash paid for income taxes246573
Preferred stock received on accounts receivable(4)17,500$—

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and its industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, Tempus’ expected financial results for full year 2026; expectations concerning Tempus' collaborations and partnerships; Tempus' competitive position; and the pending acquisition of Personalis. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may... (truncated)ity to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments, including Tempus' ability to consummate the acquisition of Personalis on the contemplated terms or at all and Tempus’ ability to realize the expected benefits of the acquisition of Paige AI, Ambry Genetics, Deep 6 AI, Center Health, and, if consummated, Personalis; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (the "SEC") on February 24, 2026, as well as in other filings Tempus may make with the SEC from time to time. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

Investors

Kendra Webster investorrelations@tempus.com

Media

Kelli Manalli kelli.manalli@tempus.com

Source: Tempus AI, Inc.

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.